In a significant endorsement of its potential, Bell Potter has more than doubled its valuation of 4DMedical Ltd (ASX: 4DX), a Melbourne-based technology company making waves in the medical imaging sector. Known for its innovative four-dimensional lung imaging platform, XV Technology, 4DMedical is poised to revolutionize respiratory disease management.
The company’s proprietary technology uses advanced mathematical models and algorithms to transform X-ray scans into quantitative data, offering physicians enhanced tools for diagnosing and managing lung diseases. Recent approval by the US Food and Drug Administration (FDA) has positioned 4DMedical for commercial success, according to Bell Potter.
FDA Approval: A Catalyst for Growth
The FDA’s September 2025 approval of 4DMedical’s CT:VQ product has been a pivotal moment for the company. Bell Potter draws parallels between 4DMedical’s trajectory and that of Pro Medicus Ltd (ASX: PME), a fellow ASX-listed tech company that experienced rapid growth following similar regulatory milestones.
The September 2025 approval of 4DX’s CT:VQ product by the FDA has become a major catalyst for a resurgence of interest in the 4DX tech. Commercialisation will be an ongoing process, much like the experience of ASX-listed peers including TLX, NAN, PME, and PNV.
Bell Potter highlights that 4DMedical shares similarities with TLX, another diagnostic provider, and PME, a software company with scalable technology and expanding margins. This comparison underscores the potential for 4DMedical to achieve significant market penetration and revenue growth.
Positive Reception Among Clinicians
Feedback from the medical community has been overwhelmingly positive, which bodes well for the technology’s adoption. Bell Potter’s discussions with clinicians, including Dr. Kyle Hogarth of the University of Chicago Medical Centre, reveal strong support for 4DMedical’s product suite.
Our discussions with clinicians have been supportive of long-term adoption of the 4D Medical product suite. Dr. Kyle Hogarth outlines benefits such as CT:VQ reporting from a single CT scan, rapid reporting within hours, avoidance of nuclear medicine, and contrast-free CT for perfusion.
These advantages not only improve patient outcomes but also streamline diagnostic processes, making 4DMedical’s technology a valuable addition to healthcare providers’ toolkits.
Investment Potential and Market Outlook
In light of these developments, Bell Potter has maintained its speculative buy rating for 4DMedical and increased its price target from $1.05 to $2.25. With the current share price at $1.59, this suggests a potential upside of 41% over the next year.
Based on its current share price of $1.59, this implies potential upside of 41% over the next 12 months.
Bell Potter’s confidence in 4DMedical is rooted in the company’s innovative technology, strong regulatory backing, and positive clinical feedback. As the company moves towards commercialisation in the US, it is well-positioned to capture a significant share of the medical imaging market.
Future Prospects and Industry Impact
The move represents a significant step forward for 4DMedical and highlights the growing importance of advanced imaging technologies in healthcare. As the company expands its market presence, it could set new standards for respiratory diagnostics and treatment.
Meanwhile, investors are keenly watching 4DMedical’s progress, anticipating that the company’s innovative solutions could lead to broader applications in other areas of medical imaging. The potential for scalability and margin expansion makes 4DMedical an attractive prospect for those looking to invest in cutting-edge healthcare technologies.
As the healthcare industry continues to evolve, the success of companies like 4DMedical will be crucial in shaping the future of medical diagnostics. With its promising technology and strategic market positioning, 4DMedical is a company to watch in the coming years.
